TPD52 expression in tumors was shown to be positively correlated with tumor status (pathological assessment of the primary tumour (pT, P = 0.035); metastasis (pM, P = 0.001)), and clinic stage (P = 0.024); Whereas, TPD52 expression was not associated with pathological assessment of regional lymph nodes (pN, P = 0.175) and tumor size (P = 0.708) of CRC patients. Here, TPD52 is linked to colorectal carcinoma.